Compare
Raphael Pharmaceutical Inc. vs Adia Med, Inc. vs Regencell Bioscience Holdings Ltd vs Cyanotech Corp
| Latest fiscal year | Raphael Pharmaceutical Inc. RAPH | Adia Med, Inc. ADIA | Regencell Bioscience Holdings Ltd RGC | Cyanotech Corp CYANLast annual report: year ended 2025-03-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-03-31 |
| Revenue | n/a | $700.5K | n/a | $24.21M |
| Revenue growth (YoY) | n/a | n/m | n/a | +5.0% |
| Gross margin | n/a | 27.4% | n/a | 28.4% |
| Operating margin | n/a | -52.3% | n/a | -10.4% |
| Net margin | n/a | -56.5% | n/a | -13.2% |
| Net income | -$1.28M | -$395.5K | -$11.70M | -$3.20M |
| EPS (Diluted) | $0.07 | $0.00 | -$2.37 | n/a |
| Operating cash flow | -$210.0K | -$179.2K | -$7.70M | -$1.19M |
| Free cash flow | n/a | -$192.4K | n/a | n/a |
| Cash & equivalents | n/a | $79.4K | n/a | $257.0K |
| Total assets | $53.0K | $594.8K | $14.73M | $23.49M |
| Total liabilities | n/a | $852.5K | $1.38M | $14.61M |
| Shareholders' equity | -$1.43M | -$257.7K | $13.35M | $8.88M |
| Return on year-end equity | n/a | n/a | -87.7% | -36.1% |
| Shares outstanding | 20.18M | n/a | n/a | 7.20M |
Revenue, most recent five fiscal years
| Fiscal year | Raphael Pharmaceutical Inc. | Adia Med, Inc. | Regencell Bioscience Holdings Ltd | Cyanotech Corp |
|---|---|---|---|---|
| Latest | n/a | $700.5K Ended 2025-12-31 | n/a | $24.21M Ended 2025-03-31 |
| 1 year earlier | n/a | $6.4K Ended 2024-12-31 | n/a | $23.07M Ended 2024-03-31 |
| 2 years earlier | n/a | n/a | n/a | $23.18M Ended 2023-03-31 |
| 3 years earlier | n/a | n/a | n/a | $35.97M Ended 2022-03-31 |
| 4 years earlier | n/a | n/a | n/a | $32.34M Ended 2021-03-31 |